---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-015061"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:58:25.334564+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vitro BioPharma issues $218,750 senior secured convertible note at 20% OID, with warrants

## Summary
- Principal amount $218,750; purchase price $175,000 (20% original issue discount).
- Interest accrues at 20% annual rate from earlier of maturity or Event of Default; payable monthly.
- Maturity date May 16, 2024, extendable to August 16, 2024 at Company's option.
- Convertible into common stock at 70% (or 60% if extended) of Liquidity Event Price (IPO/Direct Listing).
- Warrants exercisable for 5 years; exercise price based on Liquidity Event Price or $95M valuation.

## SEC filing metadata
- accession: 0001493152-24-015061
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315224015061/0001493152-24-015061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315224015061/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-015061
- JSON: https://secwatch.observer/filing/0001493152-24-015061.json
- Plain text: https://secwatch.observer/filing/0001493152-24-015061.txt

## Key facts
- Debt Financings
  Vitro Biopharma, Inc. incurred convertible notes of $218,750 with an accredited investor at 20% maturing the earlier of (i) May 16, 2024, and (ii) the occurrence of a Liquidity Event.
  - Instrument: convertible notes
  - Principal: $218,750
  - Counterparty: an accredited investor
  - Rate: 20%
  - Maturity: the earlier of (i) May 16, 2024, and (ii) the occurrence of a Liquidity Event
  - Event: incurrence
  source text: On April 11, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to an accredited investor, in a private placement, (i) a senior secured convertible note (the “Note”) in the principal amount of $218,750, for a purchase price of $175,000 (reflecting a 20% original issue discount), and warrants to purchase shares of common stock of the Company (the “Warrants”), pursuant to a previously disclosed securities purchase agreement, dated November 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224015061/0001493152-24-015061-index.htm
- Material Agreements
  Vitro Biopharma, Inc. entered into securities purchase agreement with an accredited investor (effective 2023-11-16).
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Effective: 2023-11-16
  source text: (the “Company”) issued and sold to an accredited investor, in a private placement, (i) a senior secured convertible note (the “Note”) in the principal amount of $218,750, for a purchase price of $175,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224015061/0001493152-24-015061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.